2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

Bradwell, Susie; Hone, L.; Thorneycroft, Kirstie; Lambourne, Jonathan; Aries, James; Davies, Jeffrey K.; Cutiño-Moguel, Teresa; Riches, John C.

doi:10.1016/j.leukres.2022.106908

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of doubt, a panel discussion was performed. ALL: Acute lymphocytic leukaemia; AML: Acute myeloid leukaemia; CLL: Chronic lymphocytic leukaemia; MM: multiple myeloma; NHL: Non-Hodgkin lymphoma; HL: Hodgkin lymphoma; HFNC: High-flow nasal cannula; CPAP: continuous positive airway pressure In line with the literature [18,[34][35][36][37], we found a reduction on ICU admission rates. These findings may be explained with the lower need of high-level oxygen support (i.e.…”

Section: Discussionsupporting

confidence: 87%

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

et al. 2023

View full text Add to dashboard Cite

Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate whether vaccination and monoclonal antibodies (mAbs) have modified the outcomes of HM patients with COVID-19. This is a single-centre retrospective study in HM patients hospitalized due to SARS-CoV-2 infection from March 2020 to April 2022. Patients were divided into PRE-V-mAb group (patients hospitalized before the introduction of vaccination and mAbs) and POST-V-mAb group (patients hospitalized after the use of vaccine and mAbs). A total of 126 patients were included (65 PRE-V-mAb and 61 POST-V-mAb). POST-V-mAb patients showed a significantly lower risk of intensive care unit (ICU) admission (8.2% vs. 27.7%, p = 0.005), shorter viral shedding [17 (IQR 10–28) vs. 24 days (IQR 15–50), p = 0.011] and shorter hospitalization length [13 (IQR 7–23) vs. 20 (IQR 14–41) days, p = 0.0003] compared to the PRE-V-mAb group. Nevertheless, both in-hospital and 30-day mortality rates did not significantly differ between the two groups (29.5% POST-V-mAb vs. 36.9% PRE-V-mAb and 21.3% POST-V-mAb vs. 29.2% PRE-V-mAb, respectively). At the multivariable analysis, an active malignancy (p = 0.042), a critical COVID-19 at admission (p = 0.025) and the need for high-level of oxygen support at respiratory worsening [either HFNC/CPAP (p = 0.022) or mechanical ventilation (p = 0.011)] were independently associated with in-hospital mortality. In the subgroup of POST-V-mAb patients, receiving therapy with mAbs was a protective factor (p = 0.033). Despite the new therapeutic and preventive strategies available, HM patients with COVID-19 disease represent an extremely vulnerable group with still high mortality rates.

show abstract

Section: Discussionsupporting

confidence: 87%

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

et al. 2023

View full text Add to dashboard Cite

show abstract

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

Oliva

Dezza

Petrucci

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose. Patients with hematological malignancies (HM) and SARS-CoV-2 infection present a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate whether vaccination and monoclonal antibodies (mAbs) have modified the outcomes of HM patients with COVID-19. Methods. Single-center retrospective study in HM patients hospitalized due to SARS-CoV-2 infection from March 2020 to April 2022. Patients were divided into PRE-V-mAb group (patients hospitalized before the introduction of vaccination and mAbs) and POST-V-mAb group (patients hospitalized after the use of vaccine and mAbs). Results. A total of 126 patients were included (65 PRE-V-mAb and 61 POST-V-mAb). POST-V-mAb patients showed a significantly lower risk of Intensive Care Unit (ICU) admission (8.2% vs 27.7%, p=0.005), shorter viral shedding [17 (IQR 10-28) vs 24 days (IQR 15-50), p=0.011] and shorter hospitalization length [13 (IQR 7-23) vs 20 (IQR 14-41) days, p=0.0003] compared to the PRE-V-mAb group. Nevertheless, both in-hospital and 30-day mortality rates did not significantly differ between the two groups (29.5% POST-V-mAb vs 36.9% PRE-V-mAb and 21.3% POST-V-mAb vs 29.2% PRE-V-mAb, respectively). At the multivariable analysis an active malignancy (p=0.042), a critical COVID-19 at admission (p=0.025) and the need for high-level of oxygen support at respiratory worsening [either HFNC/CPAP (p=0.022) or Mechanical Ventilation (p=0.011)] were independently associated with in-hospital mortality. In the subgroup of POST-V-mAb patients, receiving therapy with mAbs was a protective factor (p=0.033). Conclusion. Despite the new therapeutic and preventive strategies available, HM patients with COVID-19 disease represent an extremely vulnerable group with still high mortality rates.

show abstract

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

Cited by 2 publications

References 13 publications

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

Contact Info

Product

Resources

About